INTRODUCTION
============

Thrombophilia refers to a group of inherited or acquired coagulation disorders, leading to venous and/or arterial thrombosis. The most frequent clinical manifestations of venous thrombosis are deep vein thrombosis (DVT), pulmonary embolism (PE) and in case of obstruction of placental circulation, fetal loss (FL). Arterial thrombosis can manifest as myocardial infarction (MI), ischaemic stroke or arterial embolism \[[@b1-bjmg-17-02-43]\].

Thrombophilia is a multifactorial disorder that arises from the interaction of acquired and genetic risk factors \[[@b2-bjmg-17-02-43]\]. The most common acquired risk factors include surgery, immobilization, fractures, puerperium, paralysis, prolonged bed rest and use of oral contraceptives \[[@b3-bjmg-17-02-43]\] The most important genetic risk factors contributing to thrombophilia are deficiencies of natural inhibitors of clotting factors (antithrombin, protein C, protein S), Factor V Leiden (FVL) mutation and prothrombin (FII) G20210A mutation. Deficiencies of natural inhibitors occur sparsely, but represent significant risk factor \[[@b4-bjmg-17-02-43]--[@b9-bjmg-17-02-43]\]. The FVL mutation is present 3.0--7.0% in Caucasians and 15.0--50.0% in patients with thrombosis, while the incidence of FII G20210A is 1.0--2.0% in Caucasian populations and 18.0--20.0% in patients with thrombosis \[[@b8-bjmg-17-02-43]\].

The FVL mutation yields an amino acid substitution within the cleavage site of its inhibitor-activated protein C that results in impaired inhibition of FV and increased thrombin generation leading to hyper-coagubility \[[@b10-bjmg-17-02-43]--[@b12-bjmg-17-02-43]\].

The *FII G20210A* gene variant is located in the 3′ untranslated region (3′UTR) of the *FII* gene and it has been associated with elevated plasma FII levels. This is a gain-of-function mutation, causing increased cleavage site recognition and 3′ end mRNA processing, which leads to an increased FII synthesis \[[@b13-bjmg-17-02-43]--[@b16-bjmg-17-02-43]\]. Apart from the *FII G20210A*, several variants have been detected in the 3′ end of the *FII* gene, such as: *A19911G*, *C20211T*, *T20219A*, *A20218G* and *C20209T* \[[@b17-bjmg-17-02-43]--[@b25-bjmg-17-02-43]\].

The 3′ end of the *FII* gene is a dynamic region because of its non canonical architecture, therefore, it could be a potential region for finding new variants which might contribute to thrombophilia \[[@b13-bjmg-17-02-43]--[@b15-bjmg-17-02-43]\]. Despite the fact that several genetic risk factors have been associated with thrombophilia, there are still a certain number of patients suffering from idiopathic thrombophilia, defined as unequivocal clinical picture of thrombosis with unknown risk factors. Additionally, there are no data regarding the frequency of *FII* 3′ end gene variants in patients with idiopathic thrombophilia in Serbia. The aim of this study was to screen 3′ end of *FII* gene in population of patients with idiopathic thrombophilia originating from the geographic area of Serbia.

MATERIALS AND METHODS
=====================

Patients
--------

The study group was formed by searching the database of over 4000 patients who were referred to the Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia for genetic testing of thrombophilia during the period from 2000 to 2013. Anamnestic data were gathered from all the participants and the following subjects were excluded from further investigation: the patients who developed the first thrombotic event at an age above 50 years, the patients with malignancies, diabetes, antiphospholipid antibodies, deficiency of natural inhibitors (antithrombin, protein C, protein S), and the carriers of FVL and *FII G20210A* gene mutations \[[@b26-bjmg-17-02-43]\]. Finally, the study group included 100 patients (age range 16--63, median 38 years; male/female: 45/55) with a clinical picture of recurrent thrombotic events (DVT, PE, FL) or the combination of two or three thrombotic events (DVT, PE, FL, MI and stroke).

The control group comprised 100 healthy subjects (age range: 20--66 years, median 39; male/female: 82/18) with no history of thrombotic events. Informed consent was obtained from all participants and the study protocol was approved by the local research ethics committee.

Laboratory Methods
------------------

Peripheral blood was taken on 3.8% sodium citrate as anticoagulant. Genomic DNA was purified from 200 μL of human whole blood using the QIAamp DNA blood mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol. The blood and DNA samples were stored at −20 °C until further use.

The 715 bp fragment that includes the last intron and exon, 3′UTR and the flanking region of the *FII* gene (primers: 5′-GGA AAC GAG GGG ATG CCT GT-3′ and 5′-CCT GCC ATC TTT CCT CTC AC-3′), was amplified by polymerase chain reaction (PCR). The PCR reactions were performed in a 25 μL final volume: 1 × Kapa Buffer B; 2.5 mM MgCl~2~; 200 μM dNTPs; 1U Kapa Taq polymerase (Kapa Biosystems, Boston, MA, USA), 10 pmol of forward and reverse primers and 200 ng of DNA. The thermal cycle profile was: initial denaturation at 95 °C for 5 min. and 37 cycles consisting of denaturation at 95 °C for 1 min., annealing at 61 °C for 1 min. and polymerization at 72 °C for 1 min. were applied. Final extension of the PCR products was at 72 °C for 10 min.

Sequencing of the amplified 715 bp fragments was performed according to the manufacturer's protocol, using the BigDye™ Terminator Version 3.1 Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) on a 3130 Genetic Analyzer (Applied Biosystems). Two sequencing reactions for the fragment of interest were performed for each sample using the forward primer (5′-TCT AGA AAC AGT TGC CTG GC-3′) or reverse primer (5′-GAA TAG CAC TGG GAG CAT TGA-3′).

Statistical Analysis
--------------------

Statistical analysis was performed using MedCalc 12.2.1.0 statistical software (MedCalc Software bvba, Ostend, Belgium). The prevalence of detected gene variants was compared between patients and controls with the use of Fisher's exact test. The odds ratio (OR) and 95% CI (95% confidence interval) were also estimated. A *p* value of \<0.05 was considered to be statistically significant. Deviations of genotype distributions from Hardy-Weinberg equilibrium were assessed by the c^2^-test.

RESULTS
=======

In this study, we included 100 patients with idiopathic thrombophilia and 100 healthy controls. The clinical data of the study group are shown in [Table 1](#t1-bjmg-17-02-43){ref-type="table"}. In our study, we detected the presence of A19911G and C20068T variants in the 3′ end of the *FII* gene ([Figure 1](#f1-bjmg-17-02-43){ref-type="fig"}).

In the patient group, there were 51.0% heterozygous and 20.0% homozygous carriers of the A19911G variant, which was similar to the frequency in the control group (51.0% heterozygous and 19.0% homozygous) ([Table 2](#t2-bjmg-17-02-43){ref-type="table"}). The results of our study showed that the difference between patients and controls was not statistically significant (*p* = 0.88) and that A19911G does not represent a risk factor for idiopathic thrombophilia in our study (OR = 1.06; 95% CI 0.53--2.13). Regarding this variant, both groups were in Hardy-Weinberg equilibrium (c^2^ = 0.08; *p* = 0.77).

The C20068T variant was detected only in the heterozygous state, with frequencies of 4.0% in patients and 1.0% in the control group ([Table 2](#t2-bjmg-17-02-43){ref-type="table"}). Even though this difference between patients and controls was not statistically significant (*p* = 0.21), it could represent a risk factor in idiopathic thrombophilia (OR = 4.12; 95% CI 0.45--37.52). The study groups were in Hardy-Weinberg equilibrium for this variant (c^2^ = 0.04; *p* = 0.83).

In our study, 4.0% of the patients were carriers of both A19911G and C20068T mutations. This subset of patients was distinguished by more severe thrombotic manifestations. In one, DVT reoccurred six times and three patients suffered from the combination of more than two thrombotic events (MI, DVT, PE, FL, and stroke).

DISCUSSION
==========

In order to identify potential thrombophilic risk factors in these patients, we chose to sequence the 3′ end of the *FII* gene, since it has been shown that this region is very susceptible to gain-of-function mutations \[[@b13-bjmg-17-02-43]--[@b15-bjmg-17-02-43]\]. We detected two variants in the 3′ end of the *FII* gene, *A19911G* and *C20068T*, in both the patients and control groups.

The *A19911G* gene mutation is located in the last intron of the *FII* gene and functional analyses showed that the presence of this variant enhances splicing efficiency by altering a known functional pentamer motif \[[@b24-bjmg-17-02-43]\]. In our study, the frequency of the *A19911G* gene variant in patients was similar to the frequencies in the control group. The frequency of the G allele in our study was 0.44, which is very similar to the frequencies that were reported for thrombophilia patients in other populations: Italian (0.51), Spanish (0.52) and Dutch (0.48) \[[@b22-bjmg-17-02-43]--[@b23-bjmg-17-02-43]\]. According to our results, A19911G does not represent a risk factor for idiopathic thrombophilia ([Table 2](#t2-bjmg-17-02-43){ref-type="table"}). A recent study by Martinelli *et al.* \[[@b23-bjmg-17-02-43]\] that investigated the risk of cerebral sinus-venous thrombosis in patients with A19911G, also showed that this variant does not represent a significant risk factor for this thrombotic disorder. However, the MEGA study \[[@b25-bjmg-17-02-43]\], which included over 5000 patients and 5000 controls showed that the presence of the 19911GG genotype represents 1.43-fold greater risk for thrombotic occurrence (95% CI 1.27--1.67) compared to the 19911AA genotype.

The *C20068T* gene variant is located in the last exon of the *FII* gene. As it does not result in a change of the amino acid sequence of a protein, it is considered as a synonymous variant. *In vitro* functional assays revealed that constructs with the *C20068T* gene variant increased expression level 1.64 times compared to the wild type construct \[[@b27-bjmg-17-02-43]\]. However, further studies are needed in order to clarify the exact mechanism of overexpression. In our study, we detected this variant only in the heterozygous state, with a higher frequency in patients than in controls. Moreover, further studies in a larger group of subjects are needed in order to elucidate the importance of this gene variant for etiology of idiopathic thrombophilia. To the best of our knowledge, there are no studies considering the prevalence of C20068T in patients with thrombophilia or any other disease.

In our study, 4.0% of the patients were carriers of a combined *20068CT/19911AG* genotype. These patients experienced more severe clinical manifestations of throm-bophilia. This result alludes to the possible role of the association of C20068T and A19911G in pathogenesis of thrombophilia. Nevertheless, functional studies are needed to yield more precise conclusions.

Other variants in the 3′ end of the *FII* gene (*C20211T*, *T20219A*, *A20218G* and *C20209T*) that were reported in previous studies were not detected in our study. Our data indicate that the prevalence of these variants is less than 1.0% in the patients with idiopathic thrombophilia in a population originating from the geographic area of Serbia.

In order to obtain a well-defined group of patients with idiopathic thrombophilia, we applied very strict selection criteria as described in the Materials and Methods section, which led to a relatively small size of the patient group. Also, the results that we obtained can be attributed to the specific criteria we used.

In conclusion, our study showed the first results for the prevalence of variants at the 3′ end of the *FII* gene in patients with idiopathic thrombophilia. These results indicate that the *A19911G* gene variant is not a significant risk factor in our study group. On the other hand, the C20068T polymorphism could be a potential risk factor in idiopathic thrombophilia and therefore, further studies in a larger group of patients should be conducted.
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![Part of the *FII* gene sequence with: a) the *FII A19911G* gene variant in heterozygous state; b) the *FII A19911G* gene variant in homozygous state; c) the *FII C20068T* gene variant in heterozygous state.](bjmg-17-02-43f1){#f1-bjmg-17-02-43}

###### 

Data of the Patients.

  **Thrombotic Event**                                         **Number of Patients**   **Male/Female**   **Age Range (median)**
  ------------------------------------------------------------ ------------------------ ----------------- ------------------------
  Recurrent DVT                                                50                       26/24             16--63 (39)
  Recurrent PE                                                 6                        3/3               25--41 (36)
  Recurrent FL                                                 4                        0/4               29--41 (35.5)
  Combination of thrombotic events (DVT, PE, FL, MI, stroke)   40                       16/24             19--54 (38)

DVT: deep vein thrombosis; PE: pulmonary embolism; FL: fetal loss; MI: myocardial infarction.

###### 

The frequencies of detected gene variants in the studied population.

  **Gene Variant**   **Patients/Controls**   **OR; 95% CI**      ***p* Value**
  ------------------ ----------------------- ------------------- ---------------
  *A19911G*                                                      
  AG                 51/51                   −                   −
  GG                 20/19                   1.06; 0.53--2.13    0.858
                                                                 
  *C20068T*                                                      
  CT                 4/1                     4.12; 0.45--37.37   0.208
  TT                 0/0                     −                   −
